Top Markets
#1 Akedo Akedo +59.32%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.39%
#4 Velvet Velvet +43.06%
#5 Black Phoenix Black Phoenix +34.58%
#6 τemplar τemplar +22.94%
#7 Cap Cap +19.28%
#8 Ribbita by Virtuals Ribbita by Virtuals +17.53%
#9 Cross Cross +17.30%
#10 Bitway Bitway +15.59%
Coin of the day
Akedo Akedo
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Classement en actions #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Prix de l'action
$0.41
Dernière synchronisation: 2025-01-23
Capitalisation boursière
$1.08M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange CohBar, Inc. (CWBR)

Catégorie

Healthcare
Revenus pour CohBar, Inc. (CWBR)
Revenus en Jun 2023 TTM : 0.00
Selon les derniers rapports financiers de CohBar, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0.00. En 2021, l'entreprise a réalisé un chiffre d'affaires de 0.00 égal à le chiffre d'affaires de l'année 2020, qui était de 0.00. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour CohBar, Inc. de 2012 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE